For Research Use Only — Not for human or veterinary use.

Research News

Selank vs. Semax: Comparing Two Russian Neuropeptide Research Lines

A side-by-side look at Selank and Semax — two ACTH/tuftsin-derived heptapeptides from the same research tradition, their distinct mechanisms, and the one study that examined both together.

SLK-10
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • Selank and Semax are both synthetic heptapeptides developed within Russian neuropharmacology research programs, but derived from different parent molecules — tuftsin for Selank, ACTH(4-10) for Semax.[4][1]
  • Semax's literature centers on BDNF/trkB signaling, with rodent studies reporting increased hippocampal BDNF protein and mRNA following administration.[1]
  • Selank's literature centers on enkephalinase inhibition, with in vitro work reporting dose-dependent inhibition of enkephalin-degrading enzymes.[3]
  • A clinical study reported Semax was associated with increased plasma BDNF and neurological recovery measures in ischemic stroke patients, while a separate clinical study reported Selank had anxiolytic effects comparable to the benzodiazepine medazepam in generalized anxiety disorder.[2][4]
  • The two compounds have been jointly examined in one human neuroimaging study, which used resting-state fMRI to compare their effects on brain functional connectivity.[7]

What It Is

Selank and Semax are frequently discussed together because they emerged from the same Russian neuropharmacology research tradition and share a structural design principle: both are short synthetic peptides built by extending a naturally occurring parent sequence with a C-terminal Pro-Gly-Pro tripeptide to improve metabolic stability. Beyond that shared design logic, however, they are derived from different parent molecules and are studied for largely different research questions — Semax from the ACTH(4-10) fragment, Selank from the immune-signaling tetrapeptide tuftsin.[1][4]

Mechanism & Pathway

The two compounds' proposed mechanisms are distinct and non-overlapping in most of the published literature. Semax's research centers on BDNF/trkB signaling: rat hippocampus studies report a single Semax dose increasing BDNF protein levels, trkB receptor phosphorylation, and BDNF/trkB mRNA expression, with researchers proposing this pathway underlies Semax's studied cognitive effects.[1] Selank's research instead centers on enkephalinase inhibition: in vitro work reports Selank dose-dependently inhibiting the enzymatic breakdown of plasma enkephalins, proposed as the mechanistic basis for its studied anxiolytic activity by preserving endogenous opioid-like signaling tone.[3] The one point of direct overlap in the literature is a 2020 human neuroimaging study that administered both compounds separately to healthy volunteers and compared resting-state fMRI functional connectivity changes — this remains the only published work examining the two compounds within the same study design.[7]

Research Domains

  • Semax: neurotrophic & stroke-recovery research — hippocampal BDNF/trkB signaling research, extended to a clinical study in ischemic stroke patients reporting increased plasma BDNF and neurological recovery measures.[1][2]
  • Selank: anxiolytic & enkephalinase research — enzymatic inhibition research extended to a clinical trial comparing Selank to medazepam in generalized anxiety disorder and neurasthenia.[3][4]
  • Selank: chronic-stress model research — an unpredictable chronic mild stress rat model reported Selank enhancing diazepam's anxiolytic effect when co-administered.[6]
  • Joint human neuroimaging research — the only study examining both compounds together used resting-state fMRI to compare their effects on functional brain connectivity in healthy volunteers.[7]

Comparative Notes

Despite their shared research lineage, Selank and Semax are not interchangeable in the literature — researchers citing one should not assume findings transfer to the other, since their proposed mechanisms (BDNF/trkB signaling versus enkephalinase inhibition) are distinct and were established in separate, non-overlapping study designs. See the dedicated SMX-10 and SLK-10 research overviews on this blog for each compound's full individual citation list.

SLK-10 product page → · SMX-10 product page →

Certificate of Analysis: What to Look For

Certificates of Analysis for both SMX-10 and SLK-10 research vials should report confirmed amino acid sequence and net peptide content. Both are stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.

References

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LYu, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. PMID: 16996037
  2. Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PMID: 29798983
  3. Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. PMID: 11550013
  4. Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PMID: 18454096
  5. Dolotov OV, Seredenina TS, Levitskaya NG, Kamensky AA, Andreeva LA, Alfeeva LYu, Nagaev IYu, Zolotarev YuA, Grivennikov IA, Engele J, Myasoedov NF (2003). The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Doklady Biological Sciences. PMID: 14556513
  6. Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M (2017). Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. PMID: 28280289
  7. Panikratova YaR, Lebedeva IS, Sokolov OYu, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF (2020). Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. PMID: 32342318

FAQ

No. They are structurally distinct heptapeptides derived from different parent molecules — tuftsin for Selank, ACTH(4-10) for Semax — that happen to share a research tradition and a stability-enhancing Pro-Gly-Pro design element.

Both have published clinical studies from Russian research groups: Semax in ischemic stroke recovery, Selank in generalized anxiety disorder and neurasthenia. Neither has been evaluated in large-scale international trials.[2][4]

Yes, one: a 2020 human resting-state fMRI study administered each compound separately to healthy volunteers and compared their effects on brain functional connectivity.[7]

No. Semax's literature centers on BDNF/trkB signaling, while Selank's centers on enkephalinase inhibition — two distinct, separately evidenced mechanisms.

No. Both are supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance.

Related Guides